English
简体中文
Total: £ 56.28
Published Date: 2026-04-16 | Pages: 113 | Tables: 109 | Pharma & Healthcare
The global Synthetic Peptide Vaccine market was valued at US$ 124 million in 2025 and is anticipated to reach US$ 202 million by 2032, at a CAGR of 7.4% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Synthetic Peptide Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Synthetic peptide vaccines represent fragments of protein antigen sequences, synthesizing specific B cell and T cell epitopes offer the potential to induce diseases neutralizing immuno response with completely synthetic structure. Now it is well established that short chain peptides can be used to mimic antigenic sites of viruses and thus can be used the basics for vaccines and development.
Synthetic peptide vaccine is the most ideal and safe new vaccine, and it is also one of the main directions for the development of new vaccines for the prevention and control of infectious diseases and malignant tumors.
Currently, synthetic peptide vaccines for human use are all in the research and development/trial stage, and the only commercially available vaccines are for veterinary use, mainly swine foot-and-mouth disease vaccines.
According to the type, the classification of Synthetic Peptide Vaccine includes FMD Type O, FMD Type O+A, etc. In 2024, FMD Type O Synthetic Peptide Vaccine accounted for a share of 48% in the global Synthetic Peptide Vaccine market.
Synthetic Peptide Vaccine is purchased by Government Procurement or Direct Sales. In Synthetic Peptide Vaccine market, the Government Procurement holds an important share in terms of Application. China is the largest consumption place, with a revenue market share nearly 85%.
The market is highly concentrated. Major manufacturers are United Biomedical, CAHIC, and Xinjiang Tecon. Among them, United Biomedical is the largest manufacturer, with a revenue share of 51%.
This report delivers a comprehensive overview of the global Synthetic Peptide Vaccine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Synthetic Peptide Vaccine. The Synthetic Peptide Vaccine market size, estimates, and forecasts are provided in terms of sales volume (M ml) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Synthetic Peptide Vaccine market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Synthetic Peptide Vaccine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
United Biomedical
CAHIC
Xinjiang Tecon
ISA Pharmaceuticals
Lytix Biopharma
Merck
OncoTherapy Science
Circio
Stemline Therapeutics
Treos Bio
Segment by Type
FMD Type O
FMD Type O+A
Others
by Application
Government Procurement
Direct Sales
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Synthetic Peptide Vaccine manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Synthetic Peptide Vaccine sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Synthetic Peptide Vaccine Market Overview
1.1 Product Definition
1.2 Synthetic Peptide Vaccine by Type
1.2.1 Global Synthetic Peptide Vaccine Market Value by Type: 2025 vs 2032
1.2.2 FMD Type O
1.2.3 FMD Type O+A
1.2.4 Others
1.3 Synthetic Peptide Vaccine by Application
1.3.1 Global Synthetic Peptide Vaccine Market Value by Application: 2025 vs 2032
1.3.2 Government Procurement
1.3.3 Direct Sales
1.4 Global Synthetic Peptide Vaccine Market Size Estimates and Forecasts
1.4.1 Global Synthetic Peptide Vaccine Revenue 2021–2032
1.4.2 Global Synthetic Peptide Vaccine Sales 2021–2032
1.4.3 Global Synthetic Peptide Vaccine Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Synthetic Peptide Vaccine Market Competition by Manufacturers
2.1 Global Synthetic Peptide Vaccine Sales Market Share by Manufacturers (2021–2026)
2.2 Global Synthetic Peptide Vaccine Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Synthetic Peptide Vaccine Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Synthetic Peptide Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Synthetic Peptide Vaccine, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Synthetic Peptide Vaccine, Product Types and Applications
2.7 Global Key Manufacturers of Synthetic Peptide Vaccine, Date of Entry into the Industry
2.8 Global Synthetic Peptide Vaccine Market Competitive Situation and Trends
2.8.1 Global Synthetic Peptide Vaccine Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Synthetic Peptide Vaccine Players Market Share by Revenue
2.8.3 Global Synthetic Peptide Vaccine Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Synthetic Peptide Vaccine Market Scenario by Region
3.1 Global Synthetic Peptide Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Synthetic Peptide Vaccine Sales by Region: 2021–2032
3.2.1 Global Synthetic Peptide Vaccine Sales by Region: 2021–2026
3.2.2 Global Synthetic Peptide Vaccine Sales by Region: 2027–2032
3.3 Global Synthetic Peptide Vaccine Revenue by Region: 2021–2032
3.3.1 Global Synthetic Peptide Vaccine Revenue by Region: 2021–2026
3.3.2 Global Synthetic Peptide Vaccine Revenue by Region: 2027–2032
3.4 North America Synthetic Peptide Vaccine Market Facts & Figures by Country
3.4.1 North America Synthetic Peptide Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Synthetic Peptide Vaccine Sales by Country (2021–2032)
3.4.3 North America Synthetic Peptide Vaccine Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Synthetic Peptide Vaccine Market Facts & Figures by Country
3.5.1 Europe Synthetic Peptide Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Synthetic Peptide Vaccine Sales by Country (2021–2032)
3.5.3 Europe Synthetic Peptide Vaccine Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Synthetic Peptide Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Synthetic Peptide Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Synthetic Peptide Vaccine Sales by Region (2021–2032)
3.6.3 Asia Pacific Synthetic Peptide Vaccine Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Synthetic Peptide Vaccine Market Facts & Figures by Country
3.7.1 Latin America Synthetic Peptide Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Synthetic Peptide Vaccine Sales by Country (2021–2032)
3.7.3 Latin America Synthetic Peptide Vaccine Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Synthetic Peptide Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Synthetic Peptide Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Synthetic Peptide Vaccine Sales by Country (2021–2032)
3.8.3 Middle East and Africa Synthetic Peptide Vaccine Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Synthetic Peptide Vaccine Sales by Type (2021–2032)
4.1.1 Global Synthetic Peptide Vaccine Sales by Type (2021–2026)
4.1.2 Global Synthetic Peptide Vaccine Sales by Type (2027–2032)
4.1.3 Global Synthetic Peptide Vaccine Sales Market Share by Type (2021–2032)
4.2 Global Synthetic Peptide Vaccine Revenue by Type (2021–2032)
4.2.1 Global Synthetic Peptide Vaccine Revenue by Type (2021–2026)
4.2.2 Global Synthetic Peptide Vaccine Revenue by Type (2027–2032)
4.2.3 Global Synthetic Peptide Vaccine Revenue Market Share by Type (2021–2032)
4.3 Global Synthetic Peptide Vaccine Price by Type (2021–2032)
5 Segment by Application
5.1 Global Synthetic Peptide Vaccine Sales by Application (2021–2032)
5.1.1 Global Synthetic Peptide Vaccine Sales by Application (2021–2026)
5.1.2 Global Synthetic Peptide Vaccine Sales by Application (2027–2032)
5.1.3 Global Synthetic Peptide Vaccine Sales Market Share by Application (2021–2032)
5.2 Global Synthetic Peptide Vaccine Revenue by Application (2021–2032)
5.2.1 Global Synthetic Peptide Vaccine Revenue by Application (2021–2026)
5.2.2 Global Synthetic Peptide Vaccine Revenue by Application (2027–2032)
5.2.3 Global Synthetic Peptide Vaccine Revenue Market Share by Application (2021–2032)
5.3 Global Synthetic Peptide Vaccine Price by Application (2021–2032)
6 Key Companies Profiled
6.1 United Biomedical
6.1.1 United Biomedical Company Information
6.1.2 United Biomedical Description and Business Overview
6.1.3 United Biomedical Synthetic Peptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 United Biomedical Synthetic Peptide Vaccine Product Portfolio
6.1.5 United Biomedical Recent Developments/Updates
6.2 CAHIC
6.2.1 CAHIC Company Information
6.2.2 CAHIC Description and Business Overview
6.2.3 CAHIC Synthetic Peptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 CAHIC Synthetic Peptide Vaccine Product Portfolio
6.2.5 CAHIC Recent Developments/Updates
6.3 Xinjiang Tecon
6.3.1 Xinjiang Tecon Company Information
6.3.2 Xinjiang Tecon Description and Business Overview
6.3.3 Xinjiang Tecon Synthetic Peptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Xinjiang Tecon Synthetic Peptide Vaccine Product Portfolio
6.3.5 Xinjiang Tecon Recent Developments/Updates
6.4 ISA Pharmaceuticals
6.4.1 ISA Pharmaceuticals Company Information
6.4.2 ISA Pharmaceuticals Description and Business Overview
6.4.3 ISA Pharmaceuticals Synthetic Peptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 ISA Pharmaceuticals Synthetic Peptide Vaccine Product Portfolio
6.4.5 ISA Pharmaceuticals Recent Developments/Updates
6.5 Lytix Biopharma
6.5.1 Lytix Biopharma Company Information
6.5.2 Lytix Biopharma Description and Business Overview
6.5.3 Lytix Biopharma Synthetic Peptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Lytix Biopharma Synthetic Peptide Vaccine Product Portfolio
6.5.5 Lytix Biopharma Recent Developments/Updates
6.6 Merck
6.6.1 Merck Company Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Synthetic Peptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Merck Synthetic Peptide Vaccine Product Portfolio
6.6.5 Merck Recent Developments/Updates
6.7 OncoTherapy Science
6.7.1 OncoTherapy Science Company Information
6.7.2 OncoTherapy Science Description and Business Overview
6.7.3 OncoTherapy Science Synthetic Peptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 OncoTherapy Science Synthetic Peptide Vaccine Product Portfolio
6.7.5 OncoTherapy Science Recent Developments/Updates
6.8 Circio
6.8.1 Circio Company Information
6.8.2 Circio Description and Business Overview
6.8.3 Circio Synthetic Peptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Circio Synthetic Peptide Vaccine Product Portfolio
6.8.5 Circio Recent Developments/Updates
6.9 Stemline Therapeutics
6.9.1 Stemline Therapeutics Company Information
6.9.2 Stemline Therapeutics Description and Business Overview
6.9.3 Stemline Therapeutics Synthetic Peptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Stemline Therapeutics Synthetic Peptide Vaccine Product Portfolio
6.9.5 Stemline Therapeutics Recent Developments/Updates
6.10 Treos Bio
6.10.1 Treos Bio Company Information
6.10.2 Treos Bio Description and Business Overview
6.10.3 Treos Bio Synthetic Peptide Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Treos Bio Synthetic Peptide Vaccine Product Portfolio
6.10.5 Treos Bio Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Synthetic Peptide Vaccine Industry Chain Analysis
7.2 Synthetic Peptide Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Synthetic Peptide Vaccine Production Mode & Process Analysis
7.4 Synthetic Peptide Vaccine Sales and Marketing
7.4.1 Synthetic Peptide Vaccine Sales Channels
7.4.2 Synthetic Peptide Vaccine Distributors
7.5 Synthetic Peptide Vaccine Customer Analysis
8 Synthetic Peptide Vaccine Market Dynamics
8.1 Synthetic Peptide Vaccine Industry Trends
8.2 Synthetic Peptide Vaccine Market Drivers
8.3 Synthetic Peptide Vaccine Market Challenges
8.4 Synthetic Peptide Vaccine Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Synthetic Peptide Vaccine Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Synthetic Peptide Vaccine Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Synthetic Peptide Vaccine Market Competitive Situation by Manufacturers in 2025
Table 4. Global Synthetic Peptide Vaccine Sales (M ml) of Key Manufacturers (2021–2026)
Table 5. Global Synthetic Peptide Vaccine Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Synthetic Peptide Vaccine Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Synthetic Peptide Vaccine Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Synthetic Peptide Vaccine Average Price (US$/L) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Synthetic Peptide Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Synthetic Peptide Vaccine, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Synthetic Peptide Vaccine, Product Types and Applications
Table 12. Global Key Manufacturers of Synthetic Peptide Vaccine, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Synthetic Peptide Vaccine Companies by Tier (Tier 1, Tier 2, Tier 3), based on Synthetic Peptide Vaccine Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Synthetic Peptide Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Synthetic Peptide Vaccine Sales by Region (M ml), 2021–2026
Table 18. Global Synthetic Peptide Vaccine Sales Market Share by Region (2021–2026)
Table 19. Global Synthetic Peptide Vaccine Sales by Region (M ml), 2027–2032
Table 20. Global Synthetic Peptide Vaccine Sales Market Share by Region (2027–2032)
Table 21. Global Synthetic Peptide Vaccine Revenue by Region (US$ Million), 2021–2026
Table 22. Global Synthetic Peptide Vaccine Revenue Market Share by Region (2021–2026)
Table 23. Global Synthetic Peptide Vaccine Revenue by Region (US$ Million), 2027–2032
Table 24. Global Synthetic Peptide Vaccine Revenue Market Share by Region (2027–2032)
Table 25. North America Synthetic Peptide Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Synthetic Peptide Vaccine Sales by Country (M ml), 2021–2026
Table 27. North America Synthetic Peptide Vaccine Sales by Country (M ml), 2027–2032
Table 28. North America Synthetic Peptide Vaccine Revenue by Country (US$ Million), 2021–2026
Table 29. North America Synthetic Peptide Vaccine Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Synthetic Peptide Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Synthetic Peptide Vaccine Sales by Country (M ml), 2021–2026
Table 32. Europe Synthetic Peptide Vaccine Sales by Country (M ml), 2027–2032
Table 33. Europe Synthetic Peptide Vaccine Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Synthetic Peptide Vaccine Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Synthetic Peptide Vaccine Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Synthetic Peptide Vaccine Sales by Region (M ml), 2021–2026
Table 37. Asia Pacific Synthetic Peptide Vaccine Sales by Region (M ml), 2027–2032
Table 38. Asia Pacific Synthetic Peptide Vaccine Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Synthetic Peptide Vaccine Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Synthetic Peptide Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Synthetic Peptide Vaccine Sales by Country (M ml), 2021–2026
Table 42. Latin America Synthetic Peptide Vaccine Sales by Country (M ml), 2027–2032
Table 43. Latin America Synthetic Peptide Vaccine Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Synthetic Peptide Vaccine Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Synthetic Peptide Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Synthetic Peptide Vaccine Sales by Country (M ml), 2021–2026
Table 47. Middle East and Africa Synthetic Peptide Vaccine Sales by Country (M ml), 2027–2032
Table 48. Middle East and Africa Synthetic Peptide Vaccine Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Synthetic Peptide Vaccine Revenue by Country (US$ Million), 2027–2032
Table 50. Global Synthetic Peptide Vaccine Sales (M ml) by Type (2021–2026)
Table 51. Global Synthetic Peptide Vaccine Sales (M ml) by Type (2027–2032)
Table 52. Global Synthetic Peptide Vaccine Sales Market Share by Type (2021–2026)
Table 53. Global Synthetic Peptide Vaccine Sales Market Share by Type (2027–2032)
Table 54. Global Synthetic Peptide Vaccine Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Synthetic Peptide Vaccine Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Synthetic Peptide Vaccine Revenue Market Share by Type (2021–2026)
Table 57. Global Synthetic Peptide Vaccine Revenue Market Share by Type (2027–2032)
Table 58. Global Synthetic Peptide Vaccine Price (US$/L) by Type (2021–2026)
Table 59. Global Synthetic Peptide Vaccine Price (US$/L) by Type (2027–2032)
Table 60. Global Synthetic Peptide Vaccine Sales (M ml) by Application (2021–2026)
Table 61. Global Synthetic Peptide Vaccine Sales (M ml) by Application (2027–2032)
Table 62. Global Synthetic Peptide Vaccine Sales Market Share by Application (2021–2026)
Table 63. Global Synthetic Peptide Vaccine Sales Market Share by Application (2027–2032)
Table 64. Global Synthetic Peptide Vaccine Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Synthetic Peptide Vaccine Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Synthetic Peptide Vaccine Revenue Market Share by Application (2021–2026)
Table 67. Global Synthetic Peptide Vaccine Revenue Market Share by Application (2027–2032)
Table 68. Global Synthetic Peptide Vaccine Price (US$/L) by Application (2021–2026)
Table 69. Global Synthetic Peptide Vaccine Price (US$/L) by Application (2027–2032)
Table 70. United Biomedical Company Information
Table 71. United Biomedical Description and Business Overview
Table 72. United Biomedical Synthetic Peptide Vaccine Sales (M ml), Revenue (US$ Million), Price (US$/L), and Gross Margin (2021–2026)
Table 73. United Biomedical Synthetic Peptide Vaccine Product
Table 74. United Biomedical Recent Developments/Updates
Table 75. CAHIC Company Information
Table 76. CAHIC Description and Business Overview
Table 77. CAHIC Synthetic Peptide Vaccine Sales (M ml), Revenue (US$ Million), Price (US$/L), and Gross Margin (2021–2026)
Table 78. CAHIC Synthetic Peptide Vaccine Product
Table 79. CAHIC Recent Developments/Updates
Table 80. Xinjiang Tecon Company Information
Table 81. Xinjiang Tecon Description and Business Overview
Table 82. Xinjiang Tecon Synthetic Peptide Vaccine Sales (M ml), Revenue (US$ Million), Price (US$/L), and Gross Margin (2021–2026)
Table 83. Xinjiang Tecon Synthetic Peptide Vaccine Product
Table 84. Xinjiang Tecon Recent Developments/Updates
Table 85. ISA Pharmaceuticals Company Information
Table 86. ISA Pharmaceuticals Description and Business Overview
Table 87. ISA Pharmaceuticals Synthetic Peptide Vaccine Sales (M ml), Revenue (US$ Million), Price (US$/L), and Gross Margin (2021–2026)
Table 88. ISA Pharmaceuticals Synthetic Peptide Vaccine Product
Table 89. ISA Pharmaceuticals Recent Developments/Updates
Table 90. Lytix Biopharma Company Information
Table 91. Lytix Biopharma Description and Business Overview
Table 92. Lytix Biopharma Synthetic Peptide Vaccine Sales (M ml), Revenue (US$ Million), Price (US$/L), and Gross Margin (2021–2026)
Table 93. Lytix Biopharma Synthetic Peptide Vaccine Product
Table 94. Lytix Biopharma Recent Developments/Updates
Table 95. Merck Company Information
Table 96. Merck Description and Business Overview
Table 97. Merck Synthetic Peptide Vaccine Sales (M ml), Revenue (US$ Million), Price (US$/L), and Gross Margin (2021–2026)
Table 98. Merck Synthetic Peptide Vaccine Product
Table 99. Merck Recent Developments/Updates
Table 100. OncoTherapy Science Company Information
Table 101. OncoTherapy Science Description and Business Overview
Table 102. OncoTherapy Science Synthetic Peptide Vaccine Sales (M ml), Revenue (US$ Million), Price (US$/L), and Gross Margin (2021–2026)
Table 103. OncoTherapy Science Synthetic Peptide Vaccine Product
Table 104. OncoTherapy Science Recent Developments/Updates
Table 105. Circio Company Information
Table 106. Circio Description and Business Overview
Table 107. Circio Synthetic Peptide Vaccine Sales (M ml), Revenue (US$ Million), Price (US$/L), and Gross Margin (2021–2026)
Table 108. Circio Synthetic Peptide Vaccine Product
Table 109. Circio Recent Developments/Updates
Table 110. Stemline Therapeutics Company Information
Table 111. Stemline Therapeutics Description and Business Overview
Table 112. Stemline Therapeutics Synthetic Peptide Vaccine Sales (M ml), Revenue (US$ Million), Price (US$/L), and Gross Margin (2021–2026)
Table 113. Stemline Therapeutics Synthetic Peptide Vaccine Product
Table 114. Stemline Therapeutics Recent Developments/Updates
Table 115. Treos Bio Company Information
Table 116. Treos Bio Description and Business Overview
Table 117. Treos Bio Synthetic Peptide Vaccine Sales (M ml), Revenue (US$ Million), Price (US$/L), and Gross Margin (2021–2026)
Table 118. Treos Bio Synthetic Peptide Vaccine Product
Table 119. Treos Bio Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Synthetic Peptide Vaccine Distributors List
Table 123. Synthetic Peptide Vaccine Customers List
Table 124. Synthetic Peptide Vaccine Market Trends
Table 125. Synthetic Peptide Vaccine Market Drivers
Table 126. Synthetic Peptide Vaccine Market Challenges
Table 127. Synthetic Peptide Vaccine Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
Table 131. Authors List of This Report
List of Figures
Figure 1. Product Picture of Synthetic Peptide Vaccine
Figure 2. Global Synthetic Peptide Vaccine Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Synthetic Peptide Vaccine Market Share by Type: 2025 & 2032
Figure 4. FMD Type O Product Picture
Figure 5. FMD Type O+A Product Picture
Figure 6. Others Product Picture
Figure 7. Global Synthetic Peptide Vaccine Market Value by Application (US$ Million), 2021–2032
Figure 8. Global Synthetic Peptide Vaccine Market Share by Application: 2025 & 2032
Figure 9. Government Procurement
Figure 10. Direct Sales
Figure 11. Global Synthetic Peptide Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Synthetic Peptide Vaccine Market Size (US$ Million), 2021–2032
Figure 13. Global Synthetic Peptide Vaccine Sales (M ml), 2021–2032
Figure 14. Global Synthetic Peptide Vaccine Average Price (US$/L), 2021–2032
Figure 15. Synthetic Peptide Vaccine Report Years Considered
Figure 16. Synthetic Peptide Vaccine Sales Share by Manufacturers in 2025
Figure 17. Global Synthetic Peptide Vaccine Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Synthetic Peptide Vaccine Players: Market Share by Revenue in Synthetic Peptide Vaccine in 2025
Figure 19. Synthetic Peptide Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Synthetic Peptide Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Synthetic Peptide Vaccine Sales Market Share by Country (2021–2032)
Figure 22. North America Synthetic Peptide Vaccine Revenue Market Share by Country (2021–2032)
Figure 23. United States Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Synthetic Peptide Vaccine Sales Market Share by Country (2021–2032)
Figure 26. Europe Synthetic Peptide Vaccine Revenue Market Share by Country (2021–2032)
Figure 27. Germany Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Synthetic Peptide Vaccine Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Synthetic Peptide Vaccine Revenue Market Share by Region (2021–2032)
Figure 34. China Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Indonesia Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Thailand Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Malaysia Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Synthetic Peptide Vaccine Sales Market Share by Country (2021–2032)
Figure 44. Latin America Synthetic Peptide Vaccine Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Middle East and Africa Synthetic Peptide Vaccine Sales Market Share by Country (2021–2032)
Figure 49. Middle East and Africa Synthetic Peptide Vaccine Revenue Market Share by Country (2021–2032)
Figure 50. Turkey Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Saudi Arabia Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. UAE Synthetic Peptide Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Global Sales Market Share of Synthetic Peptide Vaccine by Type (2021–2032)
Figure 54. Global Revenue Market Share of Synthetic Peptide Vaccine by Type (2021–2032)
Figure 55. Global Synthetic Peptide Vaccine Price (US$/L) by Type (2021–2032)
Figure 56. Global Sales Market Share of Synthetic Peptide Vaccine by Application (2021–2032)
Figure 57. Global Revenue Market Share of Synthetic Peptide Vaccine by Application (2021–2032)
Figure 58. Global Synthetic Peptide Vaccine Price (US$/L) by Application (2021–2032)
Figure 59. Synthetic Peptide Vaccine Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
